Istar Inc 'A'

- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 - SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2024. "The third quarter was a busy time for our team as we approach completing enrollment in our DMT310 Phase 3 STAR-1 study and were able to raise funds, which we believe will allow us to reach the topline data readout in the STAR-1 study in the first quarter of 2025," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer.» Mehr auf accesswire.com

BOCA RATON, Fla.--(BUSINESS WIRE)--VSee Health, Inc. (Nasdaq: VSEE), a provider of comprehensive telehealth services that customize workflow streams and enhance patient care, announced today that co-CEO Milton Chen, Ph.D. will be speaking on the STAR-TIDES Fireside Chat “Why Your Digital Health Transformation Will Be Slow and Likely Hacked” on Tuesday, October 22nd, 2024, starting 1:00 p.m. Pacific time (4:00 p.m. Eastern time). The event, created in collaboration with Silicon Valley Forum, wil.» Mehr auf businesswire.com

The new lab will leverage PacBio's HiFi sequencing technology to broaden access to highly accurate long-read sequencing and multi-omics solutions in Southeast Asia The new lab will leverage PacBio's HiFi sequencing technology to broaden access to highly accurate long-read sequencing and multi-omics solutions in Southeast Asia» Mehr auf globenewswire.com